|
|
 |
|
Viewing report
|
|
|
|
Strategic Analysis of the European High Throughput Screening (HTS) Market
Frost & Sullivan, Sep 2004
High Throughput Drug Screening - Allaying Risks Associated with Drug Discovery
The development of effective drugs remains a challenging, risky and expensive endeavour. High throughput drug screening (HTS) is emerging as a saviour in the field of drug discovery as pharmaceuticals and biotechnology companies compete to become the first to market new drugs. By shortening the drug discovery cycle, HTS offers the opportunity to capture the maximum market share and optimise revenue generation within the first year of entry. HTS also increases the chances of clearing clinical trials by addressing issues related to pharmacokinetics, animal toxicity and side effects. In spite of high equipment costs and poor quality of lead compounds presenting a significant challenge, HTS has the potential to yield both mechanistic insights and new drug leads with unparalleled efficiency through investment and innovation.
This Frost & Sullivan research evaluates the key drivers and challenges in the European HTS market. It also examines the important technology trends and provides strategic recommendations for designing high-impact action plans.
Outsourcing HTS to Custom Screeners Proving Extremely Cost-effective
Outsourcing HTS has emerged as a cost-effective option for multinational pharmaceuticals and biotechnology companies that are under pressure to discover and develop new therapeutics at lesser costs and within shorter time frames. Research indicates that approximately 10 per cent of the funds allocated to early stage discovery are accounted for by outsourcing. Outsourcing not only compresses the time line for drug development and reduces the overall costs, it also provides access to additional drug entities and innovative technology, explains the analyst of this research.
Market for HTS is Expanding
The HTS field continues to be highly dynamic and competitive. Information sharing between competing companies, coupled with open technology transfer meetings and publications, has greatly accelerated the development of the HTS industry, says the analyst. The success of genomic and proteomic searches provides a more comprehensive list of cellular targets. The anticipated use of functional genomics and proteomics to bridge the gap between physical-chemical activities and the drug development process is also expected to be a major driver in the HTS market.
|
|
|
|
